[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2012078121A3 - Solid oral dosage form comprising cefdinir - Google Patents

Solid oral dosage form comprising cefdinir Download PDF

Info

Publication number
WO2012078121A3
WO2012078121A3 PCT/TR2011/000273 TR2011000273W WO2012078121A3 WO 2012078121 A3 WO2012078121 A3 WO 2012078121A3 TR 2011000273 W TR2011000273 W TR 2011000273W WO 2012078121 A3 WO2012078121 A3 WO 2012078121A3
Authority
WO
WIPO (PCT)
Prior art keywords
cefdinir
dosage form
oral dosage
solid oral
compositions
Prior art date
Application number
PCT/TR2011/000273
Other languages
French (fr)
Other versions
WO2012078121A2 (en
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Publication of WO2012078121A2 publication Critical patent/WO2012078121A2/en
Publication of WO2012078121A3 publication Critical patent/WO2012078121A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

The present invention relates to pharmaceutical compositions comprising cefdinir as active agent and a production method for preparation of said compositions.
PCT/TR2011/000273 2010-12-08 2011-12-02 Solid oral dosage form comprising cefdinir WO2012078121A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2010/10212 2010-12-08
TR2010/10212A TR201010212A2 (en) 2010-12-08 2010-12-08 Solid oral dosage form containing cefdinir.

Publications (2)

Publication Number Publication Date
WO2012078121A2 WO2012078121A2 (en) 2012-06-14
WO2012078121A3 true WO2012078121A3 (en) 2012-08-23

Family

ID=45491749

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000273 WO2012078121A2 (en) 2010-12-08 2011-12-02 Solid oral dosage form comprising cefdinir

Country Status (2)

Country Link
TR (1) TR201010212A2 (en)
WO (1) WO2012078121A2 (en)

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129227A1 (en) * 1996-02-29 2003-07-10 Fujisawa Pharmaceutical Co. Ltd. Beta-lactam antibiotic-containing tablet and production thereof
US20050131079A1 (en) * 2003-12-10 2005-06-16 Pujara Chetan P. Cefdinir oral suspension
US20050245738A1 (en) * 2004-05-03 2005-11-03 Lupin Ltd Stable bioavailable crystalline form or cefdinir and a process for the preparation thereof
JP2007077123A (en) * 2005-09-16 2007-03-29 Shiono Chemical Co Ltd Amorphous cefdinir, method for producing the same and oral administration pharmaceutical composition containing the same
US20070128268A1 (en) * 2005-12-07 2007-06-07 Herwig Jennewein Pharmaceutical compositions comprising an antibiotic
CN101002745A (en) * 2005-09-26 2007-07-25 刘凤鸣 Slow release preparation of cefdinir
WO2007086078A2 (en) * 2006-01-30 2007-08-02 Panacea Biotec Ltd. Novel pharmaceutical compositions and process of preparation thereof
WO2007129176A2 (en) * 2006-04-28 2007-11-15 Wockhardt Ltd Improvements in therapy for treating resistant bacterial infections
CN101352424A (en) * 2008-09-16 2009-01-28 天津市中央药业有限公司 Cefdinir dispersible tablet and preparation method thereof
KR20090090467A (en) * 2008-02-21 2009-08-26 주식회사 중외제약 Pharmaceutical composition for improving dissolution rate of cefdinir
CN101862307A (en) * 2010-03-19 2010-10-20 杭州奥默医药技术有限公司 Bisulfate Cefdinir sodium capsule and preparation method thereof
WO2011078820A1 (en) * 2009-12-25 2011-06-30 Mahmut Bilgic Pharmaceutical formulations comprising a third generation cephalosporin and clavulanic acid
WO2011078822A1 (en) * 2009-12-25 2011-06-30 Mahmut Bilgic Pharmaceutical compositions comprising cefdinir as an active agent
EP2366379A1 (en) * 2010-02-25 2011-09-21 Sanovel Ilac Sanayi ve Ticaret A.S. Cefdinir formulation with improved dissolution rate
WO2011139249A2 (en) * 2010-05-04 2011-11-10 Mahmut Bilgic Pharmaceutical composition comprising cefdinir

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA836918B (en) 1982-09-30 1984-05-30 Fujisawa Pharmaceutical Co 7-substituted-3-vinyl-3-cephem compounds and processes for the production of the same

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129227A1 (en) * 1996-02-29 2003-07-10 Fujisawa Pharmaceutical Co. Ltd. Beta-lactam antibiotic-containing tablet and production thereof
US20050131079A1 (en) * 2003-12-10 2005-06-16 Pujara Chetan P. Cefdinir oral suspension
US20050245738A1 (en) * 2004-05-03 2005-11-03 Lupin Ltd Stable bioavailable crystalline form or cefdinir and a process for the preparation thereof
JP2007077123A (en) * 2005-09-16 2007-03-29 Shiono Chemical Co Ltd Amorphous cefdinir, method for producing the same and oral administration pharmaceutical composition containing the same
CN101002745A (en) * 2005-09-26 2007-07-25 刘凤鸣 Slow release preparation of cefdinir
US20070128268A1 (en) * 2005-12-07 2007-06-07 Herwig Jennewein Pharmaceutical compositions comprising an antibiotic
WO2007086078A2 (en) * 2006-01-30 2007-08-02 Panacea Biotec Ltd. Novel pharmaceutical compositions and process of preparation thereof
WO2007129176A2 (en) * 2006-04-28 2007-11-15 Wockhardt Ltd Improvements in therapy for treating resistant bacterial infections
KR20090090467A (en) * 2008-02-21 2009-08-26 주식회사 중외제약 Pharmaceutical composition for improving dissolution rate of cefdinir
CN101352424A (en) * 2008-09-16 2009-01-28 天津市中央药业有限公司 Cefdinir dispersible tablet and preparation method thereof
WO2011078820A1 (en) * 2009-12-25 2011-06-30 Mahmut Bilgic Pharmaceutical formulations comprising a third generation cephalosporin and clavulanic acid
WO2011078822A1 (en) * 2009-12-25 2011-06-30 Mahmut Bilgic Pharmaceutical compositions comprising cefdinir as an active agent
EP2366379A1 (en) * 2010-02-25 2011-09-21 Sanovel Ilac Sanayi ve Ticaret A.S. Cefdinir formulation with improved dissolution rate
CN101862307A (en) * 2010-03-19 2010-10-20 杭州奥默医药技术有限公司 Bisulfate Cefdinir sodium capsule and preparation method thereof
WO2011139249A2 (en) * 2010-05-04 2011-11-10 Mahmut Bilgic Pharmaceutical composition comprising cefdinir

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 200729, Derwent World Patents Index; Class B02, AN 2007-297701, XP002678225, IMAI E; NIWA H: "Non-crystalline amorphous cefdinir for use in oral administration pharmaceutical composition for providing antimicrobial effect against Gram-positive and Gram-negative bacteria in oral cavity, is free from crystalline cefdinir" *
DATABASE WPI Section Ch Week 200821, Derwent World Patents Index; Class A96, AN 2008-C78111, XP002678254, LIU F: "Slow-release preparation of cefdinir in which cefdinir material is added with slow-release framework material according to a stated percentage, then made into solid dispersant with medicine material" *
DATABASE WPI Section Ch Week 200925, Derwent World Patents Index; Class A96, AN 2009-F19584, XP002678228, PANG D; YANG F: "Dispersible tablet comprises specified amount of Cefdinir, and auxiliary materials including disintegrating agent, promoting agent, filler, and other auxiliary materials" *
DATABASE WPI Section Ch Week 201001, Derwent World Patents Index; Class A96, AN 2009-N30656, XP002678226, CHOI M S; HYEON SONG S; SEOK CHOI M; SONG S H: "Pharmaceutical composition for improving dissolution rate of cefdinir, comprises carbonate, solubilizing agent, lubricant, binder, surfactant, coloring agent, buffer agent, diluent, flavoring compound, preserver and filler" *
DATABASE WPI Section Ch Week 201080, Derwent World Patents Index; Class A96, AN 2010-P34926, XP002678227, FANG S; JIE Q; LU M; YE F; YU B; YU M: "Cefdinir sodium bisulfate capsule comprises cefdinir sodium bisulfate, filling agent, disintegrant and lubricant, where filling agent is e.g. glucose and/or lactose, and the disintegrant is e.g. hydroxyethyl cellulose and/or alginic acid" *
VIDHYA PRAKASH ET AL: "Oral and parenteral therapeutic options for outpatient urinary infections caused by Enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US, vol. 53, no. 3, 1 March 2009 (2009-03-01), pages 1278 - 1280, XP002628190, ISSN: 0066-4804, [retrieved on 20090105], DOI: 10.1128/AAC.01519-08 *

Also Published As

Publication number Publication date
WO2012078121A2 (en) 2012-06-14
TR201010212A2 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
WO2010092090A3 (en) Novel salts of sitagliptin
IL220679A (en) Production method of solid preparations containing alkaline active pharmaceutical ingredients and the solid preparations produced by the method
WO2012021715A3 (en) Stable formulations of linaclotide
WO2011098582A3 (en) Novel crystalline forms of ivabradine hydrochloride
EP2535339A4 (en) Polymorphs of dasatinib, preparation methods and pharmaceutical compositions thereof
WO2011017502A3 (en) Linaclotide-containing formulations for oral administration
WO2011157721A3 (en) Ivabradine-containing pharmaceutical composition
WO2012070062A3 (en) Novel polymorph of nilotinib hydrochloride
WO2014203275A3 (en) An improved process for the preparation of apixaban and intermediates thereof
WO2012037562A3 (en) Pharmaceutical and nutraceutical compositions of abscisic acid
WO2011141488A3 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
EP2468771A4 (en) Pharmaceutical composition containing anti-hb-egf antibody as active ingredient
WO2010049449A3 (en) Novel salts of sunitinib
MX2014010433A (en) Novel crystalline form of sitagliptin sulfate.
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
WO2010006904A3 (en) Crystalline forms of rabeprazole sodium
WO2012074830A3 (en) Modified release tranexamic acid formulation
WO2011102702A3 (en) Process for the preparation of oral solid dosage forms comprising valsartan
WO2011139249A3 (en) Pharmaceutical composition comprising cefdinir
MX2013012773A (en) Drug substances, pharmeceutical compositions and methods for preparing the same.
WO2011095985A3 (en) Rasagiline salts and processes for the preparation thereof
WO2011138797A3 (en) Delayed release oral disintegrating pharmaceutical compositions of lansoprazole
HU1000299D0 (en) Nanostructured atorvastatin, its pharmaceutically acceptable salts and pharmaceutical compositions containing them and process for their preparation
EP2568810A4 (en) Darunavir compositions
WO2012060791A3 (en) Production method for pharmaceutical compositions comprising cefdinir

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11808732

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 13-09-2013)

122 Ep: pct application non-entry in european phase

Ref document number: 11808732

Country of ref document: EP

Kind code of ref document: A2